Skip to Content
Upcoming Webinar

Opdivo Qvantig® (nivolumab + hyaluronidase-nvhy) Subcutaneous Injection

Date: July 23, 2025 | 2:00 PM

Date: Wednesday, July 23, 2025
Time: 2:00 p.m. EST

Immunotherapy remains a cornerstone of cancer treatment—but how it’s delivered continues to evolve.

In this session, Alexandra Kaiser, PharmD, MS, Senior Clinical Development Manager at Bristol Myers Squibb, will walk through the clinical development and real-world potential of a new subcutaneous co-formulation of nivolumab. This alternative to infusion offers a 3–5 minute administration time and is supported by findings from the CheckMate 67T trial.

What You’ll Learn

  • Clinical context for the FDA-approved subcutaneous formulation
  • Dosing, administration, and safety profile
  • Insights from CheckMate 67T and how they apply to current oncology workflows

 

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.